Oppenheimer Survey of Patient Therapy Combinations Show Relypsa (RLYP) Concern Overblown
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA
October 21, 2015 8:34 PM EDTFirst new medicine for the treatment of hyperkalemia, or high blood potassium levels, in more than 50 years Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept levels in the target range for up to a year in patients with hyperkalemia, allowing for chronic, daily treatment of hyperkalemia Company to hold conference call/webcast Thursday, October 22, 2015 at 8:00AM ET (5:00AM PT)
REDWOOD CITY, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) --... More
